United States Patent (19) [11] 3,956,348 Hilscher (45) May 11, 1976

Total Page:16

File Type:pdf, Size:1020Kb

United States Patent (19) [11] 3,956,348 Hilscher (45) May 11, 1976 United States Patent (19) [11] 3,956,348 Hilscher (45) May 11, 1976 54 STERODETHER SPLTTING 58 Field of Search....................... 260/.397.4, 397.5 75 Inventor: Jean-Claude Hilscher, Berlin, Germany 56 References Cited (73) Assignee: Schering Aktiengesellschaft, Berlin UNITED STATES PATENTS & Bergkamen, Germany 3,818,056 6/1974 Pierdet ct al.................. 260/.397.45 3,845,084 i0/1974 Stein................................ 260/.397.5 22 Filed: Feb. 25, 1975 (21 Appl. No. 552,960 Primary Examiner-Elbert L. Roberts Attorney, Agent, or Firm-Millen, Raptes & White (30) Foreign Application Priority Data 57 ABSTRACT Feb. 27, 1974 Germany............................ 240999 Ethers of aromatic steroids are cleaved to regenerate 52 U.S. Cl........................... 260/397.5; 260/.397.4; i.E. it is hydride dialkylalu 260/239.55 C 51 Int. Cl.’............................................. C07J 1100 10 Claims, No Drawings 3,956,348 2 1 group is in the 1, 2 or 3-position thereof, especially the STEROD ETHER SPLTTING 3-position. Specific examples of alkyl aluminum compounds of BACKGROUND OF THE INVENTION the formula AlR,R,Rs are triisobutylaluminum, diethyl This invention relates to a process for cleaving aro 5 aluminum hydride, di-n-butylaluminum hydride, and matic steroid ethers. diisobutylaluminum hydride. Aluminum hydride is also The splitting of ethers of aromatic alcohls requires, as suitable. is known, more vigorous conditions and reagents than The reaction is conducted in an inert solvent in which the splitting of purely aliphatic ethers. Frequently, alkyl the starting steroid is at least partially soluble. Solvents ethers are utilized in steroid syntheses for the protec 10 which can be used for the process of this invention are tion of hydroxy groups, because this grouping with those which are inert with respect to the reactants and stands almost all reactions. However, precisely because which have a boiling point below 160° C. Examples are of this great resistance displayed by these ethers against aromatic hydrocarbons, such as benzene, toluene, and reagents, difficulties are often encountered in the liber xylene; aliphatic hydrocarbons, such as hexane; cyclic ation of the hydroxy groups protected by such etherifi 15 hydrocarbons such as cyclopentane and cyclohexane; cation after the synthesis, without affecting other groups of the molecule during this step. The aromatic and their mixtures, as well as, for example, ligroin and steroid ethers are particularly resistant. They are split benzine. only under extreme reaction conditions, such as, for The exact nature of ether group to be cleaved is not example, by treatment with strong acids, such as hydro 20 critical. The ether group is preferably an alkyl ether of gen bromide in glacial acetic acid (See German Unex an alkanol of 1-4 carbons, preferably a methyl or ethyl amined Laid-Open Application DOS 1,924,222) or ether. However, all other ethers conventional in steroid with a hydrochloric acid-pyridine complex at high tem chemistry can be employed, including those more peratures. See J. Chem. Soc. (London), 1963, 5072; readily cleaved than alkyl ethers, e.g., benzyl ethers. Ann. Chem. 705 (1967) 211. However, many steroid 25 Specific examples of ether groups are methoxy, ethoxy, ethers are sensitive to acids, for example, those wherein isopropoxy, n-butoxy, benzyloxy and cyclopentyloxy. acids can cause rearrangements or shifting of double The ether group or groups can be at any possible bonds. The only known method for splitting of aro position of the steroid molecule, such as, for example in matic steroid ethers which is not conducted in an acidic the 1-, 2-, 3-, 6-, 7-, 11-, 16- and 17-positions. medium employs Grignard reagents at temperatures of 30 The steroid ethers employed as the starting material about 160 C. See Tetrahedron 26 (1970) 1917. have an ether substituent on an aromatic ring, prefer Accordingly, it is an object of this invention to pro ably an aromatic A-ring. Preferred are those having at vide a process for splitting of ethers of aromatic steroid least one further double bond in the steroid molecule alcohols, particularly those with at least one additional which can be conjugated or non-conjugated with re double bond in the steroid molecule which can be con 35 spect to the aromatic A-ring, such as, for example, in ducted under non-acidic, gentle conditions, and thus the 6-, 7-, 8-, 9(11)-, 14-and/or 16-position. Moreover, which does not have the aforedescribed disadvantages. the rings of the steroid molecule can be substituted in Other objects will be apparent to those skilled in the the usual manner, such as, for example, with lower art. alkyl groups, preferably methyl, e.g., in the 1-, 2-, 4-, 40 6-, 7-, 13-, 16- and 17-positions and free or esterified SUMMARY OF THE INVENTION hydroxy groups in the 1-, 2-, 3-, 4-, 6-, 7-, 8-, 1 1-, 16-, According to this invention, ethers of aromatic ste 17- 20- and/or 21-position. roid alcohols, including those which contain at least The starting steroid ethers can be ethers of steroids one further double bond in the steroid molecule and of, e.g., the estrane, the 18-lower-alkyl-estrane, and the which are thus especially sensitive to acids and which 45 19-norpregnane series. do not withstand excessively high temperatures, are Preferred as starting steroids are A-ring aromatic cleaved to regenerate the aromatic hydroxy group by steroids, e.g., of the formula reaction with an alkyl aluminum compound or alumi num hydride of the formula AlRRR wherein R, R. and Ra are alike or different and are hydrogen or 50 straight-chain or branched-chain alkyl. It was surprising that further double bonds in the steroid molecule, i.e., those which are not part of the aromatic ring system, are not concomitantly reduced. A reduction of non-aromatic double bonds would have 55 to be expected, in accordance with the published work of Ziegler et al. (liebigs Ann. Chemie, 589, 105, 159), since alkyl aluminum compounds, such as diethylalu minum hydride, attack cyclic olefins. 60 DETAILED DISCUSSION Preferred aluminum compounds of the formula AlRRR are those wherein R and R are alike and are alkyl of 1-4 carbon atoms and Ra is Hor R, especially wherein R is lower-alkyl, preferably methyl, or benzyl; those wherein R, and R, are ethyl, n-butyl or isobutyl, 65 Rand Reach are hydrogen or lower-alkyl, preferably particularly those wherein R, and R are isobutyl. methyl; R is hydrogen or o- or 6-methyl; R" is hydro Preferred starting steroids are those wherein the A gen or lower-alkyl, preferably methyl or ethyl; X is ring is aromatic, particularly those wherein the ether C=O or CHOH and Y is C=O, CR", 3,956,348 4. num compound. After the reaction is terminated, the OH ORF OR ORF excess aluminum compound is decomposed, for exam 1. 1 / / ple, with alcohol, and then with aqueous alcohol. c C y Thereafter, the steroid product is isolated from the N H H . YCH, CH, CH, reaction mixture, e.g., by distillation of the solvents and precipitation into water, drying the precipitate and CCH i-chor extraction with an organic solvent. In case of steroid 6 O alcohols stable with respect to dilute acids at lower t temperatures, the reaction mixture, after the excess oR YoRr 10 aluminum compound has been decomposed, can im mediately be precipitated into dilute acid, e.g., 2% wherein R” is hydrogen, the acyl radical of an organic strength hydrochloric acid, and then washed neutral carboxylic acid, preferably containing one to 20, most with water after filtration. The further working-up op preferably one to eight carbon atoms, and A is a double eration and purification take place according to con bond optionally present in one or more of the 6-, 7-, 8-, 5 ventional methods, such as, for example, recrystalliza 8(14)-, 9(11)-, 14-, 5- or 16-positions. tion and chromatography. By the process of this invention, it is possible to split Without further elaboration, it is believed that one aromatic steroid ethers which do not withstand high skilled in the art can, using the preceding description, temperatures and are sensitive to acids, since the pro utilize the present invention to its fullest extent. The cess of this invention is gentler and also simpler in its 20 following preferred specific embodiments are, there conductance as compared to the conventional steroid fore, to be construed as merely illustrative, and not ether splitting process using Grignard reagents. limitative of the remainder of the disclosure in any way While carbon-to-carbon double bonds present in the whatsoever. steroid molecule are not attacked, carbonyl oxygen 25 EXAMPLE 1. atoms are reduced to hydroxy groups. As will be appar 10.0 g of 3-methoxy-1,3,5(10),7-estratetraen-17B-ol ent, any such reducible groups in the starting steroid, is suspended in 100 ml. of dry toluene. Within 20 min e.g., ester, ketone, ketalized ketone, aldehyde, epoxide, utes, 125 ml. of a 20% diisobutylaluminum hydride etc., are susceptible to being and probably will be re solution in toluene is added dropwise thereto under duced concurrently with the cleavage of the ether 30 nitrogen purging and agitation at 20° C. Under further group. Accordingly, if any such groups are present in nitrogen purging and agitation, the reaction mixture is the molecule, a correspondingly larger amount of alu heated for 6 hours under reflux. Then, the mixture is minum compound may be required to both reduce such cooled to about 0°C. Under ice cooling and while con reducible group and cleave the ether group. tinuing the nitrogen purging, 25 ml. of ethanol and then Surprisingly, if an attempt is made to block a keto 35 25 ml.
Recommended publications
  • United States Patent Office 3,350,427 Patented Oct
    United States Patent Office 3,350,427 Patented Oct. 31, 1967 1. 2 3,358,427 By lower alkyl is contemplated hydrocarbon radicals PROCESS FOR THE DEHYDROHALOGENATION having preferably up to four carbon atoms including CF SEROADS methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, and WilliamOrange, H. N.J., Gebert, assignors Morris to ScheringPaias, and Corporation, Nathaniel Murrill, Bloom tertiary butyl. field, N.Y., a corporation of New Jersey Our process is particularly valuable when it is desired No Drawing. Fied Jan. 28, 1966, Ser. No. 523,573 to dehydrobrominate a 17-bromo-20-keto-steroid having 10 Claims. (C. 260-397.4) at least one hydrogen at C-16, e.g. 16oz - methyl - 17 oz bromo-5-pregnen-3,6-ol-20-one or the 3-acetate thereof to This invention relates to a novel improved process for the corresponding 16-dehydro-20-keto-steroid, e.g. 5, 16 dehydrohalogenating organic compounds. O pregnadien-36-ol-20-one or the 3-acetate thereof, which In general, the invention sought to be patented is de are known, valuable intermediates in the preparation of scribed as residing in the concept of treating an o-bromo other known therapeutically valuable compounds. For ketone having a hydrogen on the beta carbon with a example, 16-methyl - 5, 16 - pregnadien-3 (3-ol-20-one may dehydrchalogenating agent selected from the group con be catalytically hydrogenated to provide 166-methyl-5- sisting of an alkaline earth oxide, an alkaline earth hy 5 pregnen-36 - ol - 20-one which may be oxidized to 16,3- droxide, and mixtures thereof in a solvent Selected from methylprogesterone.
    [Show full text]
  • A Thesis Entitled "APPLICATIONS of GAS CHROMATOGRAPHY
    A Thesis entitled "APPLICATIONS OF GAS CHROMATOGRAPHY - MASS SPECTROMETRY IN STEROID CHEMISTRY" Submitted in part fulfilment of the requirements for admittance to the degree of Doctor of Philosophy in The University of Glasgow by T.A. Baillie, B.Sc. University of Glasgow 1973. ProQuest Number: 11017930 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 11017930 Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 ACKNOWLEDGEMENTS I would like to express my sincere thanks to Dr. C.3.W. Brooks for his guidance and encouragement at all times, and to Professors R.A. Raphael, F.R.S., and G.W. Kirby, for the opportunity to carry out this research. Thanks are also due to my many colleagues for useful discussions, and in particular to Dr. B.S. Middleditch who was associated with me in the work described in Section 3 of this thesis. The work was carried out during the tenure of an S.R.C. Research Studentship, which is gratefully acknowledged. Finally, I would like to thank Miss 3.H.
    [Show full text]
  • Spectra Library Index SDBS Library
    S p e c t r a L i b r a r y I n d e x SDBS Library KBr ライブラリー名:スタンダードライブラリーKBr 商品番号:40001-40 株式会社 エス・ティ・ジャパン 〒103-0014 東京都中央区日本橋蛎殻町 1-14-10 Tel: 03-3666-2561 Fax:03-3666-2658 http://www.stjapan.co.jp 1 【販売代理店】(株)テクノサイエンス Tel:043-206-0155Fax:043-206-0188 http://www.techno-lab-co.jp/ (((3,4-DIHYDROXY-9,10-DIOXO-9,10-DIHYDRO-2-ANTHRYL)METHYL)IMINO)DIACETIC ACID (((N-BENZYLOXYCARBONYL-L-PHENYLALANYL)-O-ACETYL-L-THREONYL)-L-PROLYL-L-PHENYLALANYL)-N(OMEGA)-NITRO-L-ARGININE 4-NITROBENZYL ESTER ((1,2-DIETHYLETHYLENE)BIS(P-PHENYLENE))DIACETATE ((1-BENZOTRIAZOLYL)OXY)TRIS(DIMETHYLAMINO)PHOSPHONIUM HEXAFLUOROPHOSPHATE ((2-(3-BENZYLSULFONYL-4-METHYLCYCLOHEXYL)PROPYL)SULFONYLMETHYL)BENZENE ((2,4,6-TRIOXOHEXAHYDRO-5-PYRIMIDINYL)IMINO)DIACETIC ACID ((2-BENZOTHIAZOLYL)AMINOMETHYLENE)MALONONITRILE ((2-CARBOXYETHYL)IMINO)DIACETIC ACID ((2-CYANOETHYLAMINO)(3-INDOLYL)METHYLENE)MALONONITRILE ((2-HYDROXYETHYL)IMINO)DIACETIC ACID ((2-HYDROXYETHYLAMINO)(3-INDOLYL)METHYLENE)MALONONITRILE ((2-NITROBENZYL)IMINO)DIACETIC ACID ((2-OXOPROPYL)IMINO)DIACETIC ACID ((2-PYRIDYLAMINO)METHYLENE)MALONONITRILE ((2-QUINOLINYL)AMINOMETHYLENE)MALONONITRILE ((2-SULFOETHYL)IMINO)DIACETIC ACID ((2-THIAZOLYLAMINO)METHYLENE)MALONONITRILE ((3-(1-BROMO-1-METHYLETHYL)-7-OXO-1,3,5-CYCLOHEPTATRIEN-1-YL)OXY)DIFLUOROBORANE ((3-INDOLYL)(1-PYRROLIDINYL)METHYLENE)MALONONITRILE ((3-INDOLYL)(METHYLTHIO)METHYLENE)MALONONITRILE ((3-INDOLYL)MORPHOLINOMETHYLENE)MALONONITRILE ((3-INDOLYL)PIPERIDINOMETHYLENE)MALONONITRILE ((3-METHYL-2-PYRIDYLAMINO)METHYLENE)MALONONITRILE ((4-METHYL-2-PYRIDYLAMINO)METHYLENE)MALONONITRILE
    [Show full text]
  • Evolution of Minimal Specificity and Promiscuity in Steroid Hormone Receptors Geeta N
    Evolution of Minimal Specificity and Promiscuity in Steroid Hormone Receptors Geeta N. Eick, University of Oregon Jennifer K. Colucci, Emory University Michael J. Harms, University of Oregon Eric Ortlund, Emory University Joseph W. Thornton, University of Oregon Journal Title: PLoS Genetics Volume: Volume 8, Number 11 Publisher: Public Library of Science | 2012-11-01, Pages e1003072-e1003072 Type of Work: Article | Final Publisher PDF Publisher DOI: 10.1371/journal.pgen.1003072 Permanent URL: https://pid.emory.edu/ark:/25593/s568v Final published version: http://dx.doi.org/10.1371/journal.pgen.1003072 Copyright information: © 2012 Eick et al. This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). Accessed October 2, 2021 1:09 AM EDT Evolution of Minimal Specificity and Promiscuity in Steroid Hormone Receptors Geeta N. Eick1,2, Jennifer K. Colucci3, Michael J. Harms1, Eric A. Ortlund3, Joseph W. Thornton1,2,4* 1 Institute of Ecology and Evolution, University of Oregon, Eugene, Oregon, United States of America, 2 Howard Hughes Medical Institute, Eugene, Oregon, United States of America, 3 Biochemistry Department, Emory University School of Medicine, Atlanta, Georgia, United States of America, 4 Department of Human Genetics and Department of Ecology and Evolution, University of Chicago, Chicago, Illinois, United States of America Abstract Most proteins are regulated by physical interactions with other molecules; some are highly specific, but others interact with many partners. Despite much speculation, we know little about how and why specificity/promiscuity evolves in natural proteins. It is widely assumed that specific proteins evolved from more promiscuous ancient forms and that most proteins’ specificity has been tuned to an optimal state by selection.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter free, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6” x 9” black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. UMI A Bell & Howell Information Company 300 North Zeeb Road, Ann Arbor MI 48106-1346 USA 313/761-4700 800/521-0600 DEVELOPMENT OF STEROIDAL INHIBITORS OF CYTOCHROME P450-DEPENDENT ANDROGEN AND ESTROGEN BIOSYNTHESIS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Patrick John Ward, A.B.
    [Show full text]
  • Evolution of Minimal Specificity and Promiscuity in Steroid Hormone Receptors
    Evolution of Minimal Specificity and Promiscuity in Steroid Hormone Receptors Geeta N. Eick1,2, Jennifer K. Colucci3, Michael J. Harms1, Eric A. Ortlund3, Joseph W. Thornton1,2,4* 1 Institute of Ecology and Evolution, University of Oregon, Eugene, Oregon, United States of America, 2 Howard Hughes Medical Institute, Eugene, Oregon, United States of America, 3 Biochemistry Department, Emory University School of Medicine, Atlanta, Georgia, United States of America, 4 Department of Human Genetics and Department of Ecology and Evolution, University of Chicago, Chicago, Illinois, United States of America Abstract Most proteins are regulated by physical interactions with other molecules; some are highly specific, but others interact with many partners. Despite much speculation, we know little about how and why specificity/promiscuity evolves in natural proteins. It is widely assumed that specific proteins evolved from more promiscuous ancient forms and that most proteins’ specificity has been tuned to an optimal state by selection. Here we use ancestral protein reconstruction to trace the evolutionary history of ligand recognition in the steroid hormone receptors (SRs), a family of hormone-regulated animal transcription factors. We resurrected the deepest ancestral proteins in the SR family and characterized the structure-activity relationships by which they distinguished among ligands. We found that that the most ancient split in SR evolution involved a discrete switch from an ancient receptor for aromatized estrogens—including xenobiotics—to a derived receptor that recognized non-aromatized progestagens and corticosteroids. The family’s history, viewed in relation to the evolution of their ligands, suggests that SRs evolved according to a principle of minimal specificity: at each point in time, receptors evolved ligand recognition criteria that were just specific enough to parse the set of endogenous substances to which they were exposed.
    [Show full text]
  • Acne and Its Therapy Basic and Clinical Dermatology
    ACNE AND ITS THERAPY BASIC AND CLINICAL DERMATOLOGY Series Editors ALAN R. SHALITA, M.D. Distinguished Teaching Professor and Chairman Department of Dermatology SUNY Downstate Medical Center Brooklyn, New York DAVID A. NORRIS, M.D. Director of Research Professor of Dermatology The University of Colorado Health Sciences Center Denver, Colorado 1. Cutaneous Investigation in Health and Disease: Noninvasive Methods and Instrumentation, edited by Jean-Luc Le´veˆque 2. Irritant Contact Dermatitis, edited by Edward M. Jackson and Ronald Goldner 3. Fundamentals of Dermatology: A Study Guide, Franklin S. Glickman and Alan R. Shalita 4. Aging Skin: Properties and Functional Changes, edited by Jean-Luc Le´veˆque and Pierre G. Agache 5. Retinoids: Progress in Research and Clinical Applications, edited by Maria A. Livrea and Lester Packer 6. Clinical Photomedicine, edited by Henry W. Lim and Nicholas A. Soter 7. Cutaneous Antifungal Agents: Selected Compounds in Clinical Practice and Development, edited by John W. Rippon and Robert A. Fromtling 8. Oxidative Stress in Dermatology, edited by Ju¨rgen Fuchs and Lester Packer 9. Connective Tissue Diseases of the Skin, edited by Charles M. Lapie`re and Thomas Krieg 10. Epidermal Growth Factors and Cytokines, edited by Thomas A. Luger and Thomas Schwarz 11. Skin Changes and Diseases in Pregnancy, edited by Marwali Harahap and Robert C. Wallach 12. Fungal Disease: Biology, Immunology, and Diagnosis, edited by Paul H. Jacobs and Lexie Nall 13. Immunomodulatory and Cytotoxic Agents in Dermatology, edited by Charles J. McDonald 14. Cutaneous Infection and Therapy, edited by Raza Aly, Karl R. Beutner, and Howard I. Maibach 15.
    [Show full text]
  • NICE Guideline Template
    National Institute for Health and Care Excellence DocumentDraft for consultation information (version number/stage of process) Addendum to Clinical Guideline 44, Heavy menstrual bleeding: assessment and management Clinical Guideline Addendum 44.1 Methods, evidence and recommendations May 2016 Draft for Consultation Developed by the National Institute for Health and Care Excellence Clinical Guideline 44.1 Heavy menstrual bleeding Contents Disclaimer Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and, where appropriate, their guardian or carer. Copyright © National Institute for Health and Care Excellence, 2016. Clinical guideline 44.1 Heavy menstrual bleeding Contents Contents Clinical guidelines update .................................................................................................. 6 1 Summary section.......................................................................................................... 7 1.1 Update information ................................................................................................ 7 1.2 Recommendations ................................................................................................ 8 1.3 Patient-centred care ...........................................................................................
    [Show full text]
  • Synthesis and 5Α-Reductase Inhibitory Activity of C21 Steroids Having 1,4-Diene Or 4,6-Diene 20-Ones and 4-Azasteroid 20-Oximes
    Molecules 2012, 17, 355-368; doi:10.3390/molecules17010355 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Article Synthesis and 5α-Reductase Inhibitory Activity of C21 Steroids Having 1,4-diene or 4,6-diene 20-ones and 4-Azasteroid 20-Oximes Sujeong Kim 1, Yong-ung Kim 2,* and Eunsook Ma 1,* 1 College of Pharmacy, Catholic University of Daegu, Hayang, 712-702, Korea 2 College of Herbal Bio-industry, Daegu Hany University, Gyeongsangbuk-do 712-715, Korea * Authors to whom correspondence should be addressed; E-Mails: [email protected] (Y.-U.K.); [email protected] (E.M.); Tel.: Tel. +82-53-819-1404 (Y.-U.K.); +82-53-850-3621 (E.M.); Fax: Fax: +82-53-819-1272 (Y.-U.K.); +82-53-850-3602(E.M.). Received: 1 November 2011; in revised form: 14 December 2011 / Accepted: 16 December 2011 / Published: 30 December 2011 Abstract: The synthesis and evaluation of 5α-reductase inhibitory activity of some 4-azasteroid-20-ones and 20-oximes and 3β-hydroxy-, 3β-acetoxy-, or epoxy-substituted C21 steroidal 20-ones and 20-oximes having double bonds in the A and/or B ring are described. Inhibitory activity of synthesized compounds was assessed using 5α-reductase enzyme and [1,2,6,7-3H]testosterone as substrate. All synthesized compounds were less active than finasteride (IC50: 1.2 nM). Three 4-azasteroid-2-oximes (compounds 4, 6 and 8) showed good inhibitory activity (IC50: 26, 10 and 11 nM) and were more active than corresponding 4-azasteroid 20-ones (compounds 3, 5 and 7).
    [Show full text]